Oren Caspi

Dr. Oren Caspi

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
GCGil Caspi
Gil Caspi
ADAvshalom Dayan
Avshalom Dayan
YEYael Eshal
Yael Eshal
SLSigal Liverant-Taub
Sigal Liverant-Taub
GTGilad Twig
Gilad Twig
OCOren Caspi
Oren Caspi

11 May 2024 in JACC: Heart Failure
Verified
Journal Article
Closed access
AAAharon (Ronnie) Abbo
Aharon (Ronnie) Abbo
AGAmit Gruber
Amit Gruber
IVIna Volis
Ina Volis
DADoron Aronson
Doron Aronson
NGNicolas Girerd
Nicolas Girerd
OCOren Caspi
Oren Caspi

8 January 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JSJacob Marthinsen Seefeldt
Jacob Marthinsen Seefeldt
YLYaara Libai
Yaara Libai
KBKatrine Berg
Katrine Berg
NJNichlas Riise Jespersen
Nichlas Riise Jespersen
TLThomas Ravn Lassen
Thomas Ravn Lassen
NMNiels Moeslund
Niels Moeslund
Normothermic regional perfusion (NRP) allows assessment of therapeutic interventions prior to donation after circulatory death transplantation. Sodium-3-hydroxybutyrate (3-OHB) increases cardiac output in heart failure patients and diminishes ischemia–reperfusion injury, presumably by improving mitochondrial metabolism. We investigated effects of 3-OHB on cardiac and mitochondrial function in transplanted hearts and in cardiac organoids. Donor pigs (n = 14) underwent circulatory death followed by NRP. Following static cold storage, hearts were transplanted into recipient pigs. 3-OHB or Ringer’s acetate infusions were initiated during NRP and after transplantation. We evaluated hemodynamics and mitochondrial function. 3-OHB mediated effects on contractility, relaxation, calcium, and conduction were tested in cardiac organoids from human pluripotent stem cells. Following NRP, 3-OHB increased cardiac output (P < 0.0001) by increasing stroke volume (P = 0.006), dP/dt (P = 0.02) and reducing arterial elastance (P = 0.02). Following transplantation, infusion of 3-OHB maintained mitochondrial respiration (P = 0.009) but caused inotropy-resistant vasoplegia that prevented weaning. In cardiac organoids, 3-OHB increased contraction amplitude (P = 0.002) and shortened contraction duration (P = 0.013) without affecting calcium handling or conduction velocity. 3-OHB had beneficial cardiac effects and may have a potential to secure cardiac function during heart transplantation. Further studies are needed to optimize administration practice in donors and recipients and to validate the effect on mitochondrial function.

30 March 2020 in medRxiv
Verified
Preprint
Open access
PDF file
GCGil Caspi
Gil Caspi
USUri Shalit
Uri Shalit
SKSøren Lund Kristensen
Søren Lund Kristensen
DADoron Aronson
Doron Aronson
LCLilac Caspi
Lilac Caspi
OCOren Caspi
Oren Caspi
Background: COVID-19 outbreak poses an unprecedented challenge for societies, healthcare organizations and economies. In the present analysis we coupled climate data with COVID-19 spread rates worldwide, and in a single country (USA). Methods: Data of confirmed COVID-19 cases was derived from the COVID-19 Global Cases by the CSSE at Johns Hopkins University up to March 19, 2020. We assessed disease spread by two measures: replication rate (RR), the slope of the logarithmic curve of confirmed cases, and the rate of spread (RoS), the slope of the linear regression of the logarithmic curve. Results: Based on predefined criteria, the mean COVID-19 RR was significantly lower in warm climate countries (0.12±0.02) compared with cold countries (0.24±0.01), (P<0.0001). Similarly, RoS was significantly lower in warm climate countries 0.12±0.02 vs. 0.25 ± 0.01 than in cold climate countries (P<0.001). In all countries (independent of climate classification) both RR and RoS displayed a moderate negative correlation with temperature R= -0.69, 95% confidence interval [CI], -0.87 to -0.36; P<0.001 and R= -0.72, 95% confidence interval [CI], -0.87 to -0.36; P<0.001, respectively. We identified a similar moderate negative correlation with the dew point temperature. Additional climate variables did not display a significant correlation with neither RR nor RoS. Finally, in an ancillary analysis, COVID-19 intra-country model using an inter-state analysis of the USA did not identify yet correlation between climate parameters and RR or RoS as of March, 19, 2020. Conclusions: Our analysis suggests a plausible negative correlation between warmer climate and COVID-19 spread rate as defined by RR and RoS worldwide. This initial correlation should be interpreted cautiously and be further validated over time, the pandemic is at different stages in various countries as well as in regions within these countries. As such, some associations may be more affected by local transmission patterns rather than by climate. Importantly, we provide an online surveillance dashboard ( https://covid19.net.technion.ac.il/ ) to further assess the association between climate parameters and outbreak dynamics worldwide as time goes by. Research in context: Evidence before this study: The coronavirus, COVID-19 pandemic caused by the novel SARS-CoV 2, challenges healthcare organizations and economies worldwide. There have been previous reports describing the association between seasonal climactic variance and SARS-CoV 1 as well as the MERS infections, but the association with SARS-CoV 2 and climate has not been described extensively. Added value of this study: Our analysis demonstrates a plausible negative correlation between warmer climate and COVID-19 spread rate as defined by RR and RoS worldwide in all countries with local transmission as of March 9, 2020. This initial correlation should be interpreted cautiously and be further validated over time. Importantly, we provide an online surveillance dashboard available at ( https://covid19.net.technion.ac.il/ ) for further dynamic tracking of climate effect on COVID-19 disease spread rate worldwide and on intra-country analysis between USA states. Implications of all the available evidence: Our findings of decreased replication and spread rates of COVID-19 in warm climates may suggest that the inevitable seasonal variance will alter the dynamic of the disease spread in both hemispheres in the coming months. However, we warrant a cautious interpretation of these findings given the fact that we are in the initial steps of this outbreak in many “warm” climate countries, the high variance of the data and the dynamic changes in the disease surveillance and the lack of correlation based on the limited data in the US. We hope that the online tool coupling COVID-19 data with climate data will assist in tracking the disease and tailoring the needed measures to contain it.

1 February 2021 in medRxiv
Verified
Preprint
Open access
PDF file
GCGil Caspi
Gil Caspi
ADAvshalom Dayan
Avshalom Dayan
YEYael Eshal
Yael Eshal
SLSigal Liverant-Taub
Sigal Liverant-Taub
GTGilad Twig
Gilad Twig
OCOren Caspi
Oren Caspi
COVID-19 vaccination acceptance has a key role in mitigating the pandemic. Concern has been raised that vaccination rates will be limited in demographically defined areas of lower income. Israel’s rapid vaccination campaign may allow to assess these assumptions in real-world and to devise tools for effectively focusing the vaccination efforts. We analyzed the correlation between COVID-19 vaccination rates, socioeconomic status (SES) and active COVID-19 disease burden. We carried out a nationwide study, based on data provided by Ministry of Health of COVID-19 vaccination rates in all municipalities in Israel up to January 12 th , 2021. Municipal Vaccination rates of population older than 60 significantly correlated with the socioeconomic status (r=0.83, 95% confidence interval [0.79 to 0.87]). Finally, we established a novel metric for focusing the vaccination efforts based on % vaccinations and active disease burden. In Israel, a case-model country for COVD-19 vaccinations, vaccination rates were strongly correlated with SES. The study findings demonstrate the need to directly target vaccination acceptance to socio-economically disadvantaged populations and suggest potential tools for policymakers to focus their efforts.

1 March 2025 in Circulation: Heart Failure
Verified
Journal Article
Closed access
IHIdan Refael Haim
Idan Refael Haim
AGAmit Gruber
Amit Gruber
NKNoam Kazma
Noam Kazma
CBCaroline Bashai
Caroline Bashai
HKHava Lichtig Kinsbruner
Hava Lichtig Kinsbruner
OCOren Caspi
Oren Caspi
BACKGROUND: The therapeutic armamentarium for heart failure with preserved ejection fraction (HFpEF) remains notably constrained. A factor contributing to this problem could be the scarcity of in vitro models for HFpEF, which hinders progress in developing new therapeutic strategies. Here, we aimed at developing a novel, comorbidity-inspired, human, in vitro model for HFpEF. METHODS: Human induced pluripotent stem cells–derived cardiomyocytes were used to produce cardiac organoids. The generated organoids were then subjected to HFpEF-associated, comorbidity-inspired conditions, such as hypertension, diabetes, and obesity-related inflammation. To assess the development of HFpEF pathophysiological features, organoids were thoroughly evaluated for their structural, functional, electrophysiological, and metabolic properties. RESULTS: Exposure to the combination of all comorbidity-mimicking conditions resulted in the largest cellular volume of 1692±52 versus 1346±84 µm 3 in RPMI (Roswell Park Memorial Institute medium) control group ( P =0.003), while lower in obesity, hypertension, and diabetes groups: 1059±40 µm 3 ( P =0.014), 1276±35 µm 3 ( P =0.940), and 1575±70 µm 3 ( P =0.146), respectively. Similarly, ultrastructural fibrosis was most significantly observed after exposure to the combination of all HFpEF-inducing conditions 14.6±1.2% compared with single condition exposure 5.2±1.3% (obesity), 6.7±3.5% (hypertension), and 9.0±1.1% (diabetes; P <0.001). Moreover, HFpEF-related conditions led to an increase in passive force compared with control (7.52±1.08 versus 2.33±0.46 mN/mm, P <0.001), whereas no significant alterations were noted in active contractile forces. Relaxation constant τ was significantly prolonged after exposure to HFpEF conditions showing a prolongation of 95.9 ms (36.4–106.4; P =0.028) compared with a shortening of 35.6 ms (43.3–67.3; P =0.80) in the control. Finally, organoid exposure to HFpEF conditions led to a significant increase in oxidative stress levels and a significant decline in oxygen consumption rate. CONCLUSIONS: We established a novel, human, in vitro model for HFpEF, based on comorbidity-inspired conditions. The model faithfully recapitulated the structural, functional, and mechanistic features of HFpEF. This model holds the potential to provide mechanistic insights and facilitate the identification of novel therapeutic targets.